Speaker Profile
JD,MBA, CEO and Co-Founder, Archetype Tx
Biography
Tom Neyarapally is the CEO and Co-Founder of Archetype Therapeutics, an AI-native company pioneering the use of generative chemogenomics in patient data-driven drug discovery and repurposing in cancer and other diseases. The Archetype platform enables virtual phenotypic screening of billions of molecules per day for their effect on clinical outcomes in cohorts of patients with unmet medical need. Previously Tom was CCO and founding team member at Sema4, a patient-centered health intelligence and genetic testing company. He was also a member of the founding team and Executive Vice President, Corporate Development at the causal AI drug discovery company Aitia. After graduate school, Tom served as a corporate and IP lawyer at Chadbourne Parke LLP and Frommer Lawrence Haug LLP. He started his career after his undergraduate chemical engineering studies as an analyst focused on pharmaceuticals at the management consulting firm Arthur D. Little.
Talk
Diagnostics Driven Drug Discovery Using Generative Chemogenomics
Validated clinical genomic tests built using real world outcome data effectively predict poor patient outcomes. Generative chemogenomics virtually tests the ability of billions of compounds to reverse the molecular fate of patients with poor predicted outcomes. New drug candidates and insights into existing drug programs are generated without waiting years for outcomes.
AI and Data Sciences Showcase:
Archetype Therapeutics
Archetype Therapeutics is an AI-native biotech company that is with its Archetype™ platform pioneering the use of generative chemogenomics and patient clinicogenomic data to enable the virtual screening of billions of potential drugs per day.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
